Media Top News In The News Media Resources TOP NEWS July 09, 2026Biohaven Announces Scientific Leadership Transitions June 30, 2026Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator June 29, 2026Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease VIEW ALL WE ARE SOCIAL
